anonymous
Guest
anonymous
Guest
it will be nice to have the spring off.
Well it looks like the cemiplimab BLA did not get completed in Q1 as was the plan reported to investors.
The longer it takes, the heavier the Merck hammer is gonna strike.
Bet hey, there’s still Eyelea, so REGN does not really need to be a player in oncology. Of course they sold a story to investors so if cemiplimab is a turd, some REGN market cap will get flushed.
if the BLA is accepted and priority review is granted, then its 6 months max. Without priority review likely 10 months. Rolling BLA could shorten either scenario by 2 months.
So earliest approval is July which means you can interview with other companies in the meantime.
Wow I have been seeking the PDUFA date and couldn’t find anything. Is this true BLA isn’t filed?
Wow I have been seeking the PDUFA date and couldn’t find anything. Is this true BLA isn’t filed?
True - they have to announce it once filed as it is material information. They can keep the PDUFA confidential. See 2nd paragraph below.
http://files.shareholder.com/downlo...B5D/REGN_News_2017_12_13_General_Releases.pdf
Poolside summer
Glad I cut and ran last month.